Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810

Journal for ImmunoTherapy of Cancer

Volumn 4, Issue 1, 2016, Pages

  Falchook, Gerald S ^a   Leidner, Rom ^b   Stankevich, Elizabeth ^c   Piening, Brian ^b   Bifulco, Carlo ^b   Lowy, Israel ^c   Fury, Matthew G ^c  

^a HealthOne   (United States)

^b PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^c REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Basal cell carcinoma; Cutaneous squamous cell carcinoma; Immune checkpoint inhibitor; Mutation burden; Phase 1; Programmed Death 1; REGN2810

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY REGN 2810; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; VISMODEGIB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CASE REPORT; CERVICAL SPINAL CORD; CHEMOSURGERY; DISEASE SURVEILLANCE; FEMALE; FOLLOW UP; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG METASTASIS; LYMPHOCYTOPENIA; MALE; MIDDLE AGED; NEXT GENERATION SEQUENCING; PAROTIDECTOMY; PRIORITY JOURNAL; RADIODIAGNOSIS; RISK FACTOR; SKIN CARCINOMA; SOMATIC MUTATION; ANTAGONISTS AND INHIBITORS; CANCER STAGING; METABOLISM; METASTASIS; PATHOLOGY; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84997821097     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-016-0176-3     Document Type: Article

References (19)

1. Chalmers ZR, Huang FW, Gay LM, Ali SM, Yelensky R. Broad analysis of recurrent somatic mutations in cancer reveals a common novel non-coding mutation in the promoter of PMS2 associated with greatly increased tumor mutation load. AACR Annual Meeting. 2016;abstract 3576.
2. Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Re S, Tsai KT, Curry JL, Tetzlaff MT, Lai SY, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Canc Res. 2014;20:6582-92.
3. Bonilla X, Parmantier L, King B, Bezrukov F, Kaya G. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Gen. 2016;48:398-406.
4. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H. PD-1 blockade in tumors with mismatch-repair deficiency. New Engl J Med. 2015;372(26):2509-20.
5. Mandal R, Chan TA. Personalized oncology meets immunology: the path towards precision immunotherapy. Cancer Discov. 2016;6:1-12.
6. Fisher MS, Kripke ML. Suppressor T lymphocytes control the development of primary skin cancers in ultaviolet-irradiated mice. Science. 1982;216:1133-4.
7. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. New Engl J Med. 2003;348:1681-91.
8. Gollnick HA, Barona CG, Frank RGJ, Ruzicka T, Megahed M, Maus J, Munzel U. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol. 2008;18:677-82.
9. Walter A, Barysch MJ, Behnke S, Dziunycz P, Schmid B. Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinoma. Clin Canc Res. 2010;16:3562-70.
10. Chang ALS, Kim J, Luciano R, Sullivan-Chang R, Colevas AD. A case report of unresectable cutaneous squamous cell carcinoma responsive to pembrolizumab, a programmed cell death protein 1 inhibitor. JAMA Dermatol. 2015;152(1):106-8.
11. Lipson EJ, Bagnaso SM, Moore J, Jang S, Patel MJ. Tumor regresssion and allograft rejection after administration of anti-PD-1. New Engl J Med. 2016;374:896-8.
12. Borradori L, Sutton B, Shayesteh P, Daniels GA. Rescue therapy with anti-programmed cell death protein 1 inhibitors (PD-1) of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience of 5 cases. Br J Dermatol. 2016;[Epub ahead of print]
13. Winkler JK, Schneiderbauer R, Bender C, Sedlaczek O, Frohling S. Anti-PD-1 therapy in nonmelanoma skin cancer. Br J Dermatol. 2016;[Epub ahead of print]
14. Campesato LF, Barroso-Sousa R, Jimenez L, Correa BR, Sabbaga J. Comprehensive cancer-gene panles can e used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget. 2015;6(33):34221-7.
15. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ. PD-1 blockade with pembrolizumab in advanced Merkel cell carcinoma. N Engl J Med. 2016;374:2542-52.
16. Kaufman H, Russell JS, Hamid O, Bhatia S, Terheyden P. Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial. J Clin Oncol. 2016;34: abstract 9508.
17. Wong SQ, Waldeck K, Vergara IA, Schroder J, Madore J. UV-associated mutations underlie the etiology of MCV-negative Merkel Cell Carcinomas. Cancer Res. 2015;75:5228-34.
18. Papadopoulos KP, Crittenden M, Johnson M, Lockhart A, Moore K. A first-in-human study of REGN2810, a fully human monoclonal antibody against programmed death-1 (PD-1) in combination with immunomodulators including hypofractionated radiotherapy (hfRT). J Clin Oncol. 2016;34: abstract 3024.
19. Otsuka A, Dreier J, Cheng PF, Nageli M, Lehmann H. Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma. Clin Canc Res. 2015;15:1289-97.